Eagle Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Eagle Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-59,931	Closed	-$2.89M	–	568
2020 Q2	$2.89M	Sell	59,931 -957,556	-94%	-$46M	0.02%	419
2020 Q1	$43M	Buy	1,017,487 +12,081	+1%	+$498K	0.27%	143
2019 Q4	$43M	Sell	1,005,406 -5,257	-0.5%	-$229K	0.21%	183
2019 Q3	$36.4M	Buy	1,010,663 +10,545	+1%	+$320K	0.19%	181
2019 Q2	$26.7M	Buy	+1,000,118	New	+$25.5M	0.14%	216
2016 Q4	–	Sell	-979,303	Closed	-$31.2M	–	629
2016 Q3	$31.2M	Buy	979,303 +24,276	+3%	+$823K	0.21%	150
2016 Q2	$31M	Sell	955,027 -76,346	-7%	-$2.55M	0.21%	144
2016 Q1	$28.8M	Buy	1,031,373 +369,857	+56%	+$8.06M	0.2%	158
2015 Q4	$23.6M	Buy	661,516 +45,162	+7%	+$1.59M	0.16%	192
2015 Q3	$20.4M	Buy	+616,354	New	+$25.6M	0.14%	210

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Eagle Asset Management's ACAD Position: Q3 2020 in Review

Eagle Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q3 2020, closing a stake of 59,931 shares — an estimated $2.89M sold.

Eagle Asset Management first reported a position in ACAD in Q3 2015 and held it in 10 quarters. The position peaked at $43M in Q4 2019. 266 funds tracked by Wall St. Rank hold ACAD as of Q3 2020.

Eagle Asset Management reported no remaining Acadia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Eagle Asset Management sold 59,931 Acadia Pharmaceuticals shares in Q3 2020, an estimated $2.89M.
Eagle Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2015 and held it in 10 quarters.
Eagle Asset Management's Acadia Pharmaceuticals position peaked at $43M in Q4 2019.
266 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2020.

Based on Eagle Asset Management's 13F filing for Q3 2020, filed 12 Nov 2020.